Pancreatic Cancer mRNA Vaccine Shows Durable Response in Early Trial
Updated
Updated · NBC News · Apr 18
Pancreatic Cancer mRNA Vaccine Shows Durable Response in Early Trial
8 articles · Updated · NBC News · Apr 18
A personalized mRNA vaccine for pancreatic cancer has shown promising long-term results in an early clinical trial.
After six years, most patients who mounted an immune response to the vaccine remain alive, with some experiencing no cancer recurrence.
The findings suggest mRNA immunotherapy could offer new hope for one of the deadliest cancers, though more research is needed to confirm results.
If tumors can evolve to escape the vaccine, is this a permanent cure?
What secrets do the non-responders' tumors hold for defeating this deadly cancer?
A bespoke vaccine or an 'off-the-shelf' pill: which is the real future of cancer therapy?
Will personalized cancer vaccines become a luxury treatment only the wealthy can afford?
The vaccine failed for half its patients. What is the plan for them now?
How can we mass-produce a medicine that is unique for every single patient?
Personalized mRNA Vaccine Autogene Cevumeran Shows 3-Year Immune Persistence and Advances to Global Phase 2 Trial for Pancreatic Cancer
Overview
The personalized mRNA vaccine autogene cevumeran showed promising Phase 1 results by generating durable T-cell responses that correlated with delayed tumor recurrence in pancreatic cancer patients. This success led Genentech and BioNTech to launch a global Phase 2 trial to further evaluate the vaccine's effectiveness. However, the complex manufacturing process takes about nine weeks and results in high costs, which may limit global accessibility. Efforts are underway to reduce production time and expenses through regional manufacturing hubs and automation. Additionally, analysis of Phase 1 data suggests that patients who had their spleens removed may respond less effectively to the vaccine. Preliminary Phase 2 results are expected around 2027.